BidaskClub upgraded shares of Cellectis (NASDAQ:CLLS) from a buy rating to a strong-buy rating in a report published on Saturday.
Several other research firms have also recently commented on CLLS. Oppenheimer reiterated an outperform rating and set a $40.00 price target on shares of Cellectis in a report on Thursday, December 28th. Zacks Investment Research cut shares of Cellectis from a hold rating to a sell rating in a report on Wednesday. Jefferies Group reiterated a buy rating and set a $47.00 price target on shares of Cellectis in a report on Sunday, October 29th. Finally, ValuEngine cut shares of Cellectis from a hold rating to a sell rating in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Cellectis has an average rating of Buy and a consensus price target of $39.29.
Cellectis (NASDAQ:CLLS) opened at $32.65 on Friday. Cellectis has a twelve month low of $19.76 and a twelve month high of $35.07. The company has a market cap of $1,173.05, a P/E ratio of -13.55 and a beta of 2.07.
COPYRIGHT VIOLATION WARNING: “Cellectis (CLLS) Rating Increased to Strong-Buy at BidaskClub” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.com-unik.info/2018/02/18/cellectis-clls-rating-increased-to-strong-buy-at-bidaskclub.html.
Cellectis Company Profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.